Docality.com Logo
 
Dr. Azizul  Hoque  Md image

Dr. Azizul Hoque Md

1400 Wellbrook Cir Ne 103
Conyers GA 30012
770 857-7112
Medical School: Other - 1986
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: No
License #: 49032
NPI: 1730195587
Taxonomy Codes:
207RC0000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Azizul Hoque is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:93458 Description:L hrt artery/ventricle angio Average Price:$2,084.79 Average Price Allowed
By Medicare:
$303.66
HCPCS Code:99223 Description:Initial hospital care Average Price:$504.51 Average Price Allowed
By Medicare:
$195.95
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$414.45 Average Price Allowed
By Medicare:
$161.48
HCPCS Code:93224 Description:Ecg monit/reprt up to 48 hrs Average Price:$345.44 Average Price Allowed
By Medicare:
$100.24
HCPCS Code:93015 Description:Cardiovascular stress test Average Price:$324.40 Average Price Allowed
By Medicare:
$89.43
HCPCS Code:99222 Description:Initial hospital care Average Price:$344.39 Average Price Allowed
By Medicare:
$133.43
HCPCS Code:93306 Description:Tte w/doppler complete Average Price:$237.00 Average Price Allowed
By Medicare:
$64.97
HCPCS Code:93306 Description:Tte w/doppler complete Average Price:$236.92 Average Price Allowed
By Medicare:
$64.98
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$267.42 Average Price Allowed
By Medicare:
$104.83
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$261.54 Average Price Allowed
By Medicare:
$100.42
HCPCS Code:99239 Description:Hospital discharge day Average Price:$264.53 Average Price Allowed
By Medicare:
$103.59
HCPCS Code:93280 Description:Pm device progr eval dual Average Price:$208.40 Average Price Allowed
By Medicare:
$57.61
HCPCS Code:78452 Description:Ht muscle image spect mult Average Price:$213.75 Average Price Allowed
By Medicare:
$76.90
HCPCS Code:78452 Description:Ht muscle image spect mult Average Price:$213.57 Average Price Allowed
By Medicare:
$76.90
HCPCS Code:99238 Description:Hospital discharge day Average Price:$180.92 Average Price Allowed
By Medicare:
$70.10
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$181.19 Average Price Allowed
By Medicare:
$70.93
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$180.09 Average Price Allowed
By Medicare:
$70.03
HCPCS Code:99212 Description:Office/outpatient visit est Average Price:$109.08 Average Price Allowed
By Medicare:
$42.88
HCPCS Code:93228 Description:Remote 30 day ecg rev/report Average Price:$91.40 Average Price Allowed
By Medicare:
$25.61
HCPCS Code:93016 Description:Cardiovascular stress test Average Price:$80.70 Average Price Allowed
By Medicare:
$22.23
HCPCS Code:93016 Description:Cardiovascular stress test Average Price:$80.62 Average Price Allowed
By Medicare:
$22.23
HCPCS Code:93018 Description:Cardiovascular stress test Average Price:$70.20 Average Price Allowed
By Medicare:
$15.05
HCPCS Code:93018 Description:Cardiovascular stress test Average Price:$68.07 Average Price Allowed
By Medicare:
$15.05
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$68.34 Average Price Allowed
By Medicare:
$19.23
HCPCS Code:99211 Description:Office/outpatient visit est Average Price:$51.00 Average Price Allowed
By Medicare:
$19.94
HCPCS Code:36415 Description:Routine venipuncture Average Price:$26.40 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:85610 Description:Prothrombin time Average Price:$23.38 Average Price Allowed
By Medicare:
$5.56

HCPCS Code Definitions

93015
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; with supervision, interpretation and report
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
78452
Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection
78452
Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection
93224
External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional
93280
Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead pacemaker system
93018
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only
93016
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report
93018
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only
93016
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report
93306
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography
93228
External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99222
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.
93458
Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed
93306
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99211
Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional. Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99212
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99239
Hospital discharge day management; more than 30 minutes
99238
Hospital discharge day management; 30 minutes or less

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1376591388
Pathology
4,202
1750397295
Cardiovascular Disease (Cardiology)
2,911
1063440451
Nephrology
1,813
1558384180
Vascular Surgery
1,572
1992722821
Cardiac Electrophysiology
1,538
1265430797
Pulmonary Disease
1,408
1164404521
Diagnostic Radiology
1,184
1881652519
Internal Medicine
1,088
1982699500
Internal Medicine
1,031
1992757868
Internal Medicine
1,023
*These referrals represent the top 10 that Dr. Hoque has made to other doctors

Publications

Differential effects of peroxynitrite on the function of arginine vasopressin V(1a) receptors and alpha(1)-adrenoceptors in vivo. - Vascular pharmacology
The aim of this study was to provide evidence that peroxynitrite may differentially affect the function of arginine vasopressin (AVP) V(1a) receptors and alpha(1)-adrenoceptors in vascular smooth muscle of the ratThe vasoconstrictor responses elicited by AVP, or the alpha(1)-adrenoceptor agonist, phenylephrine, were determined in anesthetized rats before and after injections of (i) peroxynitrite, the thiol chelator, para-hydroxymercurobenzoic acid (PHMBA), or the electron acceptor, nitroblue tetrazolium (NBT). The ability of the reducing agent, glutathione, to reverse the loss of response to phenylephrine and AVP in peroxynitrite-treated rats was also examined.The AVP-induced responses were suppressed 10-20 min but not 60-70 min after the administration of peroxynitrite. Glutathione reversed the above loss of response to AVP at 10-20 min. The responses elicited by phenylephrine were suppressed 10-20 min and 60-70 min after administration of peroxynitrite. Glutathione did not reverse the above losses of response to phenylephrine. In addition, the vasoconstrictor actions of AVP and phenylephrine were markedly suppressed after administration of PHMBA or nitroblue tetrazolium.The above findings provide evidence that exogenously administered peroxynitrite may differentially affect the function of AVP V(1a) receptors and alpha(1)-adrenoceptors in vascular smooth muscle of the rat. The possibility that peroxynitrite impairs AVP V(1a) receptor function by transient oxidation events whereas peroxynitrite impairs alpha(1)-adrenoceptor function by transient oxidation and permanent nitration events will be discussed.
Differentiation of L- and D-S-nitrosothiol recognition sites in vivo. - Journal of cardiovascular pharmacology
The main aim of this study was to determine the effects of the lipophobic electron acceptor, nitroblue tetrazolium (NBT), on the vasodilator responses elicited by femoral vein injections of L- and D-S-nitrosocysteine (L- and D-SNC), L- and D-S-nitroso-beta,beta-dimethylcysteine (L- and D-SNPEN) and the nitric oxide (NO) donor, MAHMA NONOate, in pentobarbital-anesthetized rats. L- and D-SNC, L- and D-SNPEN, and MAHMA NONOate elicited dose-dependent falls in mean arterial blood pressure (MAP), and hindquarter (HQR), renal (RR), and mesenteric (MR) vascular resistances. The L-SNC- and L-SNPEN-induced depressor and vasodilator responses were markedly attenuated after injection of NBT. The D-SNC- and D-SNPEN-induced falls in mean arterial pressure, hindquarter, and mesenteric vascular resistances were also reduced after injection of nitroblue tetrazolium whereas the falls in renal resistances were not affected. However, nitroblue tetrazolium inhibited the L-SNC and L-SNPEN responses much more profoundly than the D-SNC and D-SNPEN responses in each vascular bed. In contrast, the MAHMA NONOate-induced responses were not attenuated by nitroblue tetrazolium. This study demonstrates that nitroblue tetrazolium attenuates L- and D-SNC-and L- and D-SNPEN- mediated but not NO-mediated vasodilation. The lack of effects of NBT on the NO responses suggests that NBT does not interfere with the intracellular mechanisms by which NO relaxes vascular smooth muscle. The more pronounced effects of NBT on the vasodilator effects of L-SNC and L-SNPEN than D-SNC and D-SNPEN suggests that these stereoisomers differentially interact with stereoselective S-nitrosothiol recognition sites in the vasculature and that these sites (or their signaling elements) contain thiol residues that may be susceptible to occupation and/or oxidation (ie, disulfide-bond formation) by nitroblue tetrazolium.
Effects of thiol chelation on alpha1-adrenoceptor-induced vasoconstriction in vivo. - Journal of cardiovascular pharmacology
The aims of this study were to determine whether systemic injections of the lipophobic thiol chelator, para-hydroxymercurobenzoic acid (PHMBA) would reduce the vasoconstrictor responses elicited by the alpha1-adrenoceptor agonist, phenylephrine, in urethane-anesthetized rats by chelation of thiol residues in alpha1-adrenoceptors in vascular smooth muscle rather than voltage-sensitive Ca(2+)-channels (Ca(2+)VERSUS-channels). The magnitudes and durations of the vasoconstrictor responses elicited by phenylephrine were markedly reduced after the injections of PHMBA. In contrast, the maximal phenylephrine-induced responses were not affected whereas the durations of these responses were markedly attenuated after injection of the Ca(2+)VERSUS-channel blocker, nifedipine. Nifedipine elicited pronounced and sustained falls in mean arterial blood pressure and vascular resistances in PHMBA-treated rats. Moreover, the vasodilator actions of the nitric oxide-donor, sodium nitroprusside were minimally attenuated by PHMBA whereas they were markedly attenuated by nifedipine. These findings support evidence that the vasoconstrictor responses due to activation of alpha1-adrenoceptors are initiated by mobilization of intracellular pools of Ca(2+) whereas they are sustained by opening of Ca(2+)VERSUS-channels. These findings also suggest that PHMBA diminishes the vasoconstrictor effects of phenylephrine by chelation of thiol residues in alpha1-adrenoceptors rather than by blockade of Ca(2+)VERSUS-channels, and that chelation of these thiol residues prevents agonist occupation and/or activation of these receptors and subsequent mobilization of intracellular pools of Ca(2+).
Potential role of nitration and oxidation reactions in the effects of peroxynitrite on the function of beta-adrenoceptor sub-types in the rat. - European journal of pharmacology
This study examined the hemodynamic responses elicited by the beta-adrenoceptor agonist, isoproterenol (1 and 10 microg/kg, i.v.) before and after administration of (i) peroxynitrite (10 x 10 micromol/kg, i.v.), (ii) the thiol chelator, para-hydroxymercurobenzoic acid (pHMBA, 75 micromol/kg, i.v.), and (iii) the electron acceptor, nitroblue tetrazolium (NBT, 10 micromol/kg, i.v.) in pentobarbital-anesthetized rats. The tachycardia elicited by the lower dose of isoproterenol was diminished whereas the tachycardia elicited by the higher dose was not attenuated after administration of peroxynitrite. The falls in hindquarter and renal vascular resistances elicited by both doses of isoproterenol were substantially diminished whereas the isoproterenol-induced falls in mesenteric vascular resistance were not changed after administration of peroxynitrite. All of the isoproterenol-induced responses were markedly attenuated after administration of pHMBA or NBT. These findings suggest that the oxidation and/or nitration of beta-adrenoceptors impair the ability of isoproterenol to bind to and/or activate these G protein-coupled receptors. beta1-, beta2- and beta3-adrenoceptors contain extracellular cysteine residues susceptible to oxidation (i.e., disulfide-bridge formation) whereas only the beta1- and beta2-adrenoceptors contain extracellular tyrosine residues susceptible to nitration. These findings also suggest that sustained impairment of beta1- and beta2-adrenoceptor function by peroxynitrite is due to nitration of extracellular tyrosine residues in these receptors. By analogy, beta3-adrenoceptors may not be permanently affected by peroxynitrite because these receptors are devoid of extracellular tyrosine residues.
Two-dimensional and Doppler transesophageal echocardiographic delineation and flow characterization of anomalous coronary arteries in adults. - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
The purpose of this study was to examine the use of transesophageal echocardiography (TEE) in the identification and flow characterization of congenital coronary anomalies.Congenital coronary anomalies in adults are rare but may cause serious cardiac complications. The use of TEE in evaluation of this entity has not been well defined. Very little is known regarding flow patterns in anomalous coronaries assessed by Doppler TEE.A total of 32 consecutive adult patients were studied using TEE to define the origin, course, and proximal flow pattern of suspected coronary anomalies.Coronary anomalies identified using TEE included anomalous origin from the pulmonary trunk (n = 2), right sinus (n = 18), left sinus (n = 9), single coronary (n = 2), and left main coronary fistula (n = 1). Multiplane TEE performed in 20 cases simplified the delineation of more complex coronary anomalies. The origin was identified in all patients, proximal course delineated in 31, and proximal flow pattern characterized by pulsed Doppler in 23 of 32 patients. In 16 anomalous left main, left anterior descending, or left circumflex coronary arteries, an abnormal systolic flow pattern (ie, systolic/diastolic time-velocity integral ratio >1) occurred exclusively (P <.001) when the anomalous artery had an intermediate (100%; 5/5) versus anterior or posterior course (0%; 0/11) relative to the aortic and pulmonary artery trunks. A systolic flow pattern was also evident in 4 (80%) of 5 patients with an anomalous right coronary artery with an intermediate course.TEE, particularly with a multiplane probe, has an important complementary role to coronary angiography in delineating the proximal course and pattern of flow in anomalous coronaries. Predominant systolic flow pattern in anatomically left proximal anomalous coronaries signifies an intermediate course between the aorta and the pulmonary trunk and may be clinically useful for risk stratification.
Exercise echocardiography and thallium-201 single-photon emission computed tomography stress test for 5- and 10-year prognosis of mortality and specific cardiac events. - Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
Limited data suggest that stress myocardial perfusion imaging and stress echocardiography have similar prognostic value for composite cardiac events. However, it is not known whether exercise echocardiography and stress thallium are similar in their prediction of specific cardiac events, eg, death, sudden death, myocardial infarction, unstable angina, and congestive heart failure. A total of 206 patients undergoing stress echocardiography and thallium-201 single-photon emission computed tomography imaging during the same exercise test were followed-up for 5 and 10 years. Multivariate Cox regression analyses incorporating clinical, exercise stress test, echocardiographic, and nuclear imaging parameters were used to predict mortality and specific cardiac events. A moderate to large amount of ischemia (> or =4 segments on the basis of a 16-segment model) by exercise stress echocardiography was the strongest predictor of overall mortality (relative risk [RR] 6.2; P <.0001), cardiac death (RR 17.6; P =.01), congestive heart failure (RR 17.4; P =.0005) or sudden death (RR 26.8; P =.003), whereas a moderate to large fixed defect (> or =2 segments on the basis of a 6-segment model) by nuclear imaging was the strongest predictor of myocardial infarction (RR 8.1; P =.0002) or unstable angina (RR 3.0; P =.005) at 5 years. The heterogeneity in the prediction of these specific cardiac events by these 2 modalities was similarly observed at 10 years. The extent of ischemia by stress echocardiography is a better predictor of overall mortality, cardiac death, congestive heart failure, or sudden death, whereas the extent of a fixed defect by nuclear imaging is a better predictor of myocardial infarction or unstable angina.

Map & Directions

1400 Wellbrook Cir Ne 103 Conyers, GA 30012
View Directions In Google Maps

Nearby Doctors

1612 Milstead Rd Ne Suite A
Conyers, GA 30012
678 133-3261
1412 Milstead Ave Ne
Conyers, GA 30012
770 949-9326
1412 Milstead Ave Ne
Conyers, GA 30012
770 183-3627
1380 Milstead Ave Ne Suite F
Conyers, GA 30012
770 600-0123
1301 Well Brook Circle
Conyers, GA 30012
770 223-3023
1277B Wellbrook Cir Ne
Conyers, GA 30012
770 225-5745
1368-C Wellbrook Circle
Conyers, GA 30012
404 947-7033
1612 Milstead Rd Ne Suite A
Conyers, GA 30012
678 133-3261
1301 Wellbrook Circle
Conyers, GA 30012
770 223-3023
1364 Wellbrook Cir Ne
Conyers, GA 30012
770 224-4024